All-in-one automated Amperia instrument, designed for agile protein quantification & binding assays to free you from analytical delays, with real-time data
Employees: 11-50
Total raised: $8.41M
Investors 1
| Date | Name | Website |
| 30.11.2023 | Cambridge ... | cambridgea... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.12.2024 | Series A | $8.41M | - |
Mentions in press and media 8
| Date | Title | Description |
| 09.03.2026 | Engine vroom as Abselion opens US base | - |
| 22.09.2025 | Abselion introduces Protein G Total Antibody Quantification Kit | - |
| 09.09.2025 | Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits | Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for enhanced specificity and consistency Cam... |
| 09.09.2025 | Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits | - |
| 09.12.2024 | The Rise of Earth Imagery and Automated Analytics: A New Era in Technology | In the fast-paced world of technology, two companies are making waves. Spexi and Abselion are harnessing innovation to reshape industries. They recently secured significant funding, propelling their missions forward. Spexi, based in Vancouv... |
| 09.12.2024 | Abselion Raises £6.6M in Series A Funding | Ruizhi Wang, CEO, Abselion with the Amperia at-line protein analyser Abselion, a Cambridge, UK-based company which specializes in automated analytical instrumentation that simplifies at-line protein quantification, raised £6.6M in Series A ... |
| 09.12.2024 | Spexi Raises $11.5M in Series A Funding | Spexi, a Vancouver, Canada-based earth imagery company, raised $11.5M in Series A funding. The round was led by Blockchange Ventures. The company intends to use the funds to expand operations and its development efforts. Led by CEO Bill Lak... |
| - | Abselion | “Abselion” |